in Asian and Other Diverse Communities
Bridging Communication Barriers to the Diagnosis and Treatment of HBV in the Asian Community (Course HBV3.06)
Published on November 29, 2007 Podcast
Published on November 29, 2007 Podcast
Click here to view our current activities in Gastroenterology.
In this lively podcast interview, Adrian M. Di Bisceglie, MD, FACP, George K.K. Lau, MD, and Mindie Nguyen, MD, MAS, explore several obstacles in diagnosing and treating HBV in Asian-American patients. Among the barriers discussed, along with suggestions for overcoming these challenges, are the communication difficulties involved in treating non-English speaking patients, patient reliance on traditional herbal treatments, patient reluctance to undergo certain diagnostic procedures, and obtaining treatment for uninsured patients. This podcast represents Course 6 of Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities
.
Adrian M. Di Bisceglie, MD, FACP
- Acting Chairman, Internal Medicine
- Chief of Hepatology
- Saint Louis University School of Medicine
- St. Louis, Missouri
George KK Lau, MD
- Professor in Clinical Hepatology
- Assistant Dean
- Li Ka Shing Faculty of Medicine
- The University of Hong Kong
- Hong Kong, China
Mindie Nguyen, MD, MAS
- Assistant Professor of Medicine
- GI and Hepatology, Liver Transplant
- Stanford University
- Medical Center
- Palo Alto, California
George KK Lau, MD, has no significant relationships to disclose.
Mindie Nguyen, MD, MAS, has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, and Idenix/Novartis.
Robert G. Gish, MD, has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and ZymoGenetics, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International.
W. Ray Kim, MD, has received grant/research support from Gilead Sciences, Inc; is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, Roche Pharmaceuticals, and Schering-Plough Corporation.
George KK Lau, MD, has no significant relationships to disclose.
Mindie Nguyen, MD, MAS, has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, and Idenix/Novartis.
Available for CME/CE:
Physicians
Publish Date: Nov 29, 2007 Termination Date: Nov 29, 2008Nurses
Publish Date: Nov 29, 2007 Termination Date: Nov 29, 2008Estimated time for completion of this activity:
CNE: 30.00 minutes
Target Audience
This activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.
Activity Goal
The goal of this CME/CE activity is to examine the latest information about treating chronic hepatitis B virus (HBV) infection, taking into account the most current guidelines, recent FDA approvals, and new data, in order to effectively suppress viral replication.
Learning Objective (s)
- Given the reluctance of many Asian Americans to undergo certain procedures, identify alternative means of diagnosing and treating HBV in this population.
- Utilizing knowledge of the incidence of HBV, implement appropriate screening methods to evaluate first- and second-generation Asian-American patients.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
This program has been approved by the American Association of Critical-Care Nurses (AACN) for 0.50 contact hour(s). Provider #00013784.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb Company, Gilead Sciences, Inc, Idenix Pharmaceuticals, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals, Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, and Roche Pharmaceuticals; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated.
George KK Lau, MD has no significant relationships to disclose.
Mindie Nguyen, MD, MAS has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, and Idenix/Novartis.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Karen Gravelle, PhD
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals, Pharmasset Pharmaceuticals Inc, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated.
Robert G. Gish, MD has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and ZymoGenetics, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International.
W. Ray Kim, MD has received grant/research support from Gilead Sciences, Inc; is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, Roche Pharmaceuticals, and Schering-Plough Corporation.
George KK Lau, MD has no significant relationships to disclose.
Mindie Nguyen, MD, MAS has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, and Idenix/Novartis.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Nov 29, 2007 Termination Date: Nov 29, 2008Nurses
Publish Date: Nov 29, 2007 Termination Date: Nov 29, 2008Estimated time for completion of this activity:
CNE: 30.00 minutes
Target Audience
This activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.
Activity Goal
The goal of this CME/CE activity is to examine the latest information about treating chronic hepatitis B virus (HBV) infection, taking into account the most current guidelines, recent FDA approvals, and new data, in order to effectively suppress viral replication.
Learning Objective (s)
- Given the reluctance of many Asian Americans to undergo certain procedures, identify alternative means of diagnosing and treating HBV in this population.
- Utilizing knowledge of the incidence of HBV, implement appropriate screening methods to evaluate first- and second-generation Asian-American patients.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
This program has been approved by the American Association of Critical-Care Nurses (AACN) for 0.50 contact hour(s). Provider #00013784.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb Company, Gilead Sciences, Inc, Idenix Pharmaceuticals, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals, Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, and Roche Pharmaceuticals; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated.
George KK Lau, MD has no significant relationships to disclose.
Mindie Nguyen, MD, MAS has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, and Idenix/Novartis.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Karen Gravelle, PhD
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals, Pharmasset Pharmaceuticals Inc, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated.
Robert G. Gish, MD has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and ZymoGenetics, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International.
W. Ray Kim, MD has received grant/research support from Gilead Sciences, Inc; is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, Roche Pharmaceuticals, and Schering-Plough Corporation.
George KK Lau, MD has no significant relationships to disclose.
Mindie Nguyen, MD, MAS has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, and Idenix/Novartis.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|
About This Activity Language barriers and cultural differences are the primary reasons for the shortfall in universal HBV screening in high-risk populations, including individuals from Asian countries. In this lively podcast interview, Adrian M. Di Bisceglie, MD, FACP, George K.K. Lau, MD, and Mindie Nguyen, MD, MAS, explore several obstacles in diagnosing and treating HBV in Asian-American patients. Among the barriers discussed, along with suggestions for overcoming these challenges, are the communication difficulties involved in treating non-English speaking patients, patient reliance on traditional herbal treatments, patient reluctance to undergo certain diagnostic procedures, and obtaining treatment for uninsured patients. The need to screen all first- and second-generation Asian Americans, especially those from HBV endemic areas and regardless of self-reported vaccination, is emphasized... |



